{"id":690495,"date":"2022-09-29T16:08:36","date_gmt":"2022-09-29T20:08:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/"},"modified":"2022-09-29T16:08:36","modified_gmt":"2022-09-29T20:08:36","slug":"kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/","title":{"rendered":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022"},"content":{"rendered":"

<\/p>\n

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–
\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 \u2013 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation that are not available in the abstract.\n<\/p>\n

Poster Presentation Details:<\/b><\/p>\n

Abstract Title<\/b>: Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
\n
Session: <\/b>SLE \u2013 Treatment Poster II
\n
Date\/Time:<\/b> November 13, 2022 from 9:00 AM – 10:30 AM ET
\n
Presenter:<\/b> Amit Saxena, MD, Assistant Professor, NYU School of Medicine\n<\/p>\n

Abstract Title<\/b>: Poor Health-Related Quality of Life in Patients with Lupus Nephritis
\n
Session: <\/b>Patient Outcomes, Preferences, and Attitudes Poster II
\n
Date\/Time:<\/b> November 13, 2022 from 1:00 PM – 3:00 PM ET
\n
Presenter:<\/b> Cristina Arriens, MD, Clinical Associate Member, Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation\n<\/p>\n

Abstract Title: <\/b>Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
\n
Poster Session: <\/b>Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More
\n
Date\/Time:<\/b> November 12, 2022 from 1:00 PM – 3:00 PM ET
\n
Presenter:<\/b> Kenneth Kalunian, MD, Professor of Medicine, University of California San Diego\n<\/p>\n

\nThe accepted ACR abstracts are currently available on the congress platform here<\/a>. Following the conference, the presentation materials will be available in the \u201cScientific Publications\u201d section of Kezar Life Science\u2019s website at www.kezarlifesciences.com<\/a>.\n<\/p>\n

About Zetomipzomib (KZR-616)<\/b><\/p>\n

\nZetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.\n<\/p>\n

About Kezar Life Sciences<\/b><\/p>\n

\nKezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company\u2019s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20220929005862\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
Gitanjali Jain
\n
Vice President, Investor Relations and External Affairs
\n
gjain@kezarbio.com
\n<\/a><\/p>\n

Media Contact:
\n<\/b>
Julia Deutsch
\n
Solebury Strategic Communications
\n
jdeutsch@soleburystrat.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health General Health Clinical Trials Research Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 \u2013 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation … <\/p>\n

Continue reading “Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690495","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 \u2013 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation … Continue reading "Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T20:08:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022\",\"datePublished\":\"2022-09-29T20:08:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/\"},\"wordCount\":581,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/\",\"name\":\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-09-29T20:08:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/","og_locale":"en_US","og_type":"article","og_title":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 - Market Newsdesk","og_description":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 \u2013 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation … Continue reading \"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T20:08:36+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022","datePublished":"2022-09-29T20:08:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/"},"wordCount":581,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/","name":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-09-29T20:08:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220929005862r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kezar-life-sciences-to-present-complete-results-from-the-phase-2-mission-trial-of-zetomipzomib-in-patients-with-lupus-nephritis-at-the-american-college-of-rheumatology-convergence-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690495"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}